NCT02910570 - Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

March 31, 2019

Conditions

Osteoarthritis, Knee

Interventions

DRUG

Liraglutide 3 mg (Saxenda)

Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks

DRUG

Liraglutide 3 mg placebo

Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.

Trial Locations (1)

2000

Department of Rheumatology, Frederiksberg